Evidence map›Paper›PMID 30172362›Full record

Trial reportThe American journal of cardiology2018

Relation of Volume Overload to Clinical Outcomes in Acute Heart Failure (From ASCEND-HF).

Marat Fudim, Kishan S Parikh, Allison Dunning, Adam D DeVore, Robert J Mentz, Phillip J Schulte, Paul W Armstrong, Justin A Ezekowitz, W H Wilson Tang, John J V McMurray and 5 more

Abstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in The American journal of cardiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Marat FudimDuke Clinical Research Institute, Durham, North Carolina. Electronic address: marat.fudim@duke.edu.
Kishan S ParikhDuke Clinical Research Institute, Durham, North Carolina.
Allison DunningDuke Clinical Research Institute, Durham, North Carolina.
Adam D DeVoreDuke Clinical Research Institute, Durham, North Carolina.
Robert J MentzDuke Clinical Research Institute, Durham, North Carolina.
Phillip J SchulteMayo Clinic, Rochester, Minnesota.
Paul W ArmstrongCanadian VIGOUR Centre, University of Alberta, Edmonton, Alberta.
Justin A EzekowitzCanadian VIGOUR Centre, University of Alberta, Edmonton, Alberta.
W H Wilson TangDepartment of Cardiology, Cleveland Clinic, Cleveland, Ohio.
John J V McMurrayBHF Cardiovascular Research Centre, University of Glasgow, United Kingdom.
Adriaan A VoorsDepartment of Cardiology, University Medical Center Groningen, the Netherlands.
Mark H DraznerDivision of Cardiology, University of Texas Southwestern Medical Center, Dallas, Texas.
Christopher M O'ConnorInova Heart and Vascular Institute, Falls Church, Virginia.
Adrian F HernandezDuke Clinical Research Institute, Durham, North Carolina.
Chetan B PatelDuke Clinical Research Institute, Durham, North Carolina.

Funding

MULTIDISCIPLINARY HEART &VASCULAR DISEASEST32HL007101 · NHLBI · DUKE UNIVERSITY · PI FREEDMAN, NEIL J. · 1985 to 2020
$9.8M
NHLBI NIH HHS T32 HL007101
6 · The paper itself

Abstract

We aimed to study whether jugular venous distension (JVD) and peripheral edema were associated with worse outcomes in patients with acute heart failure in the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure trial. Of 7,141 patients in Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure, 7,135 had complete data on baseline JVD and peripheral edema status. Patients were grouped according to baseline examination findings: (1) no JVD or peripheral edema; (2) JVD only; (3) peripheral edema only; (4) JVD and peripheral edema. We used unadjusted and adjusted logistic or Cox regression analyses to assess associations between groups and the outcomes of index length of stay (LOS), in-hospital mortality, 30- and 180-day all-cause mortality. Patients with peripheral edema (Groups 3 and 4) had higher body mass index, NT-proBNP and BNP values, and more co-morbid disease, and reduced left ventricular ejection fraction compared with patients in Groups 1-2. The median (25th-75th) LOS for Groups 1-4 was 6 (4-9), 5 (4-8), 7 (4-11), and 6 days (4-10), respectively. For the 30-day and 180-day outcomes, adjusted analyses found no significant difference in risk for patients presenting with JVD only or peripheral edema only as compared with patients without evidence of JVD or peripheral edema (p >0.05 for all). The presence of both JVD and peripheral edema was associated with an adjusted 24% increase in risk for all-cause mortality at 30 days, but no risk difference at 180 days. In conclusion, in patients with heart failure presenting to the hospital with dyspnea, the presence of peripheral edema is associated with a longer hospital LOS, but no difference in short- and long-term clinical outcomes when compared with patients wihout peripheral edema. The combination of peripheral edema and JVD identifies the highest risk cohort for poor clinical outcomes.

Indexed as

Hospital MortalityAgedBody Mass IndexComorbidityDilatation, PathologicEdemaFemaleHeart FailureHumansJugular VeinsLength of StayLogistic ModelsMaleMiddle AgedNatriuretic Peptide, BrainPeptide FragmentsNatriuretic Peptide, BrainPeptide Fragmentspro-brain natriuretic peptide (1-76)

Identifiers

PMID30172362
PMCPMC6924269

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.